These foods increase your odds of early Parkinson's symptoms: study
Mind your mind!
Around 90,000 new cases of Parkinson's disease are diagnosed in the US each year — the neurodegenerative disorder is commonly associated with slow movement, tremors, stiffness and difficulty walking.
Experts suggest that physical activity and a balanced diet can help lower Parkinson's risk. A new study supports that guidance, finding that people who consume a lot of ultra-processed foods are more likely to have early signs of Parkinson's than those who eat less junk food.
Advertisement
3 Around 90,000 new cases of Parkinson's disease are diagnosed in the US each year — the neurodegenerative disorder is commonly associated with slow movement, tremors, stiffness and difficulty walking.
LIGHTFIELD STUDIOS – stock.adobe.com
'There's growing evidence that diet might influence the development of Parkinson's disease,' said study author Dr. Xiang Gao of the Institute of Nutrition at Fudan University in Shanghai, China.
'Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease.'
Advertisement
Nearly 43,000 volunteers with an average age of 48, who did not have Parkinson's at the start of the study, were followed for up to 26 years.
Participants underwent regular medical exams, completed health questionnaires and maintained a food diary every two to four years.
Researchers calculated the number of UPF servings they ate on an average day.
3 Before tremors and other symptoms, early signs of Parkinson's include REM sleep behavior disorder, constipation, depression, pain, impaired color vision, excessive daytime sleepiness and reduced ability to smell.
Orawan – stock.adobe.com
Advertisement
UPFs included sauces, spreads, condiments, packaged sweets, snacks, desserts, artificially or sugar-sweetened beverages and animal-based products.
A serving was equivalent to a can of soda, 1 ounce of potato chips, a slice of cake, a hot dog or a tablespoon of ketchup.
Participants were split into five groups — the highest group ate 11 or more daily servings, while the lowest group ate fewer than three servings a day.
Advertisement
The researchers also watched for early signs of Parkinson's in the participants, including REM sleep behavior disorder, constipation, depression, pain, impaired color vision, excessive daytime sleepiness and reduced ability to smell.
After adjusting for factors such as age and exercise levels, participants in the highest UPF group had a 2.5-fold higher likelihood of having three or more of these early signs than those in the lowest UPF group.
3 Ultra-processed foods include sauces, spreads, condiments, packaged sweets, snacks, desserts, artificially or sugar-sweetened beverages and animal-based products.
vaaseenaa – stock.adobe.com
Researchers also noted that a diet high in UPFs raised the risk for all the early Parkinson's symptoms except constipation.
The findings were published online Wednesday in Neurology, the medical journal of the American Academy of Neurology.
'Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health,' Gao said. 'More studies are needed to confirm our finding that eating less processed food may slow down the earliest signs of Parkinson's disease.'
UPFs often contain lots of calories, sugar, salt and unhealthy fats. They can trigger inflammation in the brain that disrupts brain function, increasing the risk of brain disorders like Parkinson's and Alzheimer's disease.
Recent research also tied UPFs to higher risks of psoriasis, depression and even early death.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders
RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital & Research Centre (KFSHRC) has become the first institution in the Middle East to successfully implant an AI-powered brain-sensing device designed for the treatment of complex neurological disorders. The breakthrough ushers in a new era of real-time, adaptive neuromodulation therapy, offering renewed hope for patients suffering from Parkinson's disease, epilepsy, and other movement disorders. The device utilizes artificial intelligence to continuously monitor the brain's electrical activity, identifying abnormal neural signals and delivering precisely targeted electrical impulses to restore neurological balance. Powered by a closed-loop system, the device automatically adjusts stimulation in real time based on the patient's brain activity, enabling highly responsive, personalized therapy and consistent symptom control throughout the day. The minimally invasive procedure, typically completed within three to five hours, has shown the potential to reduce patients' reliance on medication by as much as 50%. This cuts down detrimental side effects and enhances patients' autonomy and quality of life. Initial outcomes suggest rapid post-operative recovery and tangible improvements in symptom control within weeks. This breakthrough reflects the leadership and clinical excellence of KFSHRC's Neuroscience Centre of Excellence, which provides comprehensive, multidisciplinary care for adult and paediatric neurological cases. The Center leads the region in deep brain stimulation (DBS) for movement disorders, stereotactic EEG for epilepsy, and AI-based diagnostics for cognitive conditions and autism. Through continuous innovation and a patient-centred approach, it is redefining regional standards in neuroscience and setting new benchmarks in precision brain health. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ A photo accompanying this announcement is available at
Los Angeles Times
3 hours ago
- Los Angeles Times
Parkinson's Disease: What We Know and Where Treatment Is Headed
Parkinson's disease (PD) is more than a movement disorder—it's a neurological condition that reshapes the lives of patients and families. Parkinson's affects both motor and non-motor functions so its impact is broad and multifaceted. While tremors and stiffness may be the most visible signs, PD also brings a wide range of symptoms that impact thinking, mood and overall functioning. Common symptoms are bradykinesia, rigidity, tremor, postural instability, sleep disturbances and mood changes. As science digs deeper into this condition, hope grows for more precise, effective and compassionate care. Parkinson's disease is defined by the gradual loss of dopamine producing neurons in a part of the brain called the substantia nigra. This dopamine deficiency disrupts the brain circuits responsible for smooth and coordinated movements, leading to hallmark motor symptoms: resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability [1] [3] [5]. These are the most common Parkinson's disease symptoms targeted by treatment. The hallmark motor symptoms encompass a range of movement symptoms and movement related symptoms that affect daily functioning. Postural instability often results in balance problems making coordination and stability difficult for patients. In addition to resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability, other motor symptoms such as freezing of gait and difficulty with fine motor tasks may also occur. Collectively these are referred to as PD symptoms, the clinical features of Parkinson's disease. But PD isn't just about what the body can or can't do—it's also about what the brain feels. Long before a tremor appears many patients experience non-motor symptoms: Parkinson's symptoms, both motor and non-motor, can develop gradually and vary significantly between individuals. These symptoms can be easy to overlook or misattribute, often delaying diagnosis. According to a 2008 review, clinicians rely on a detailed medical history and physical examination to distinguish PD from other parkinsonian syndromes [1], while a 2020 JAMA review emphasizes the role of dopamine transporter (DAT) imaging and clinical expertise in diagnosis and staging [5]. Parkinson's is diagnosed primarily through evaluation of medical history and clinical examination, as there is no definitive blood test or brain scan for confirmation. So, what causes Parkinson's disease? The short answer: it's complicated. Most cases are considered idiopathic—meaning no single cause is identified—but multiple factors seem to converge. Both genetic and environmental factors are recognized as major contributors to the development of Parkinson's disease. Genetic contributions are increasingly recognized, with mutations in genes like LRRK2, PARK7 and SNCA playing a role [2]. Genetic mutations in these and other genes can influence disease development, sometimes interacting with environmental exposures. But genes don't tell the whole story. Environmental exposures, such as pesticide use or heavy metals, also contribute, especially in individuals with underlying vulnerabilities. At the cellular level PD is defined by several overlapping pathological processes: The loss of dopamine producing neurons in the substantia nigra involves the degeneration and death of specific brain cells and nerve cells which underlies the motor and non-motor symptoms of Parkinson's disease. These mechanisms interact like a feedback loop—fueling one another and accelerating neurodegeneration. This complex interplay drives the disease process, shaping both the progression and development of Parkinson's disease. Parkinson's disease affects more than 10 million people worldwide, with incidence rising sharply with age—especially after 60 [11]. Most Parkinson's disease cases are idiopathic and occur in older adults, with the majority of diagnoses in people over 60. However, early onset cases, known as early onset PD, can develop before age 50 and may differ in disease progression, diagnosis and treatment compared to typical cases. Men are more frequently affected than women, and rural living, well water exposure and pesticide contact are established risk factors. On the other hand, researchers have also identified protective factors. Regular caffeine consumption, moderate nicotine exposure and consistent physical activity may lower PD risk. Though not fully understood, these factors may influence inflammation, neuroplasticity or dopamine metabolism. There's no single test for Parkinson's, which makes early and accurate diagnosis a clinical challenge. Physicians typically rely on: In advanced diagnostic settings a spinal tap (lumbar puncture) may be performed to collect spinal fluid for biomarker analysis, such as detecting abnormal alpha-synuclein proteins. New frontiers are expanding diagnostic accuracy. Machine learning algorithms are being trained to analyze voice patterns, gait dynamics and digital biomarkers. AI-enhanced diagnostics and bioinformatics platforms are also being developed to detect early inflammatory signals before motor symptoms emerge [10]. Autonomic testing, including monitoring for blood pressure changes, may be used to assess non-motor symptoms. Distinguishing Parkinson's disease from other syndromes is crucial, with multiple system atrophy being an important differential diagnosis due to overlapping symptoms but differing disease progression and treatment responses. While there's no cure for PD, treatment can significantly improve quality of life. The primary goal of therapy is to manage symptoms and help patients maintain independence. Medications: Medication is different from surgery and should be discussed with a doctor. Dopaminergic medications can cause orthostatic hypotension and low blood pressure so monitoring is important. Non-medication is equally important: PD can also affect mood, behavior and cognition. Managing neuropsychiatric symptoms like depression or hallucinations requires a nuanced approach, including SSRIs, atypical antipsychotics and cognitive behavioral therapy. The Parkinson's Foundation is a key player in advancing research and treatment for Parkinson's disease. As the disease progresses many patients develop cognitive impairment, from mild forgetfulness to full blown Parkinson's Disease Dementia (PDD). These symptoms can overlap with or mimic Dementia with Lewy Bodies (DLB) (also known as Lewy body dementia) and Progressive Supranuclear Palsy (PSP) and other disorders within the spectrum of atypical parkinsonism, so accurate diagnosis is critical. A 2025 study compared cognitive trajectories across these syndromes and emphasized the need for tailored care and better biomarkers to distinguish between them. Inflammation is no longer seen as just a consequence of PD—it may be the cause. Recent studies, including a 2025 paper using machine learning and bioinformatics, have identified new inflammatory markers that could help with early diagnosis [10]. Ongoing Parkinson's research is key to finding new biomarkers, better treatments and a are also finding potential therapeutic targets. For example, UPS10, a protein that blocks α-synuclein degradation, may be a way to stop disease progression [8]. And lipid metabolism pathways open up metabolic interventions. These therapeutic strategies aim to modify the disease process to slow or stop progression. This is driving personalized medicine where treatment is based on a patient's genetic, metabolic or inflammatory profile. And the average life expectancy for most people with PD is the same as the general population thanks to research and care. Parkinson's disease is still a challenge for patients, caregivers and clinicians. But it's also a global research effort to understand the onset, progression and treatment of the disease. As we understand the interplay of genetics, environment and inflammation the future of PD looks more precise and hopeful. Until then a multidisciplinary approach – medication, therapy and emotional support – is the foundation of good care. [1] Jankovic J. (2008). Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry, 79(4), 368–376. [2] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. Lancet (London, England), 386(9996), 896–912. [3] Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. P., Taft, C. A., & Hage-Melim, L. I. S. (2020). Parkinson's Disease: A Review from [4] Pathophysiology to Treatment. Mini reviews in medicinal chemistry, 20(9), 754–767. [5] Balestrino, R., & Schapira, A. H. V. (2020). Parkinson disease. European journal of neurology, 27(1), 27–42. [6] Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323(6), 548–560. [7] Qin, B., Fu, Y., Raulin, A. C., Kong, S., Li, H., Liu, J., Liu, C., & Zhao, J. (2025). Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease. Chinese medical journal, 10.1097/CM9.0000000000003627. Advance online publication. [8] Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. Lancet (London, England), 397(10291), 2284–2303. [9] Anisimov, S., Takahashi, M., Kakihana, T., Katsuragi, Y., Sango, J., Abe, T., & Fujii, M. (2025). UPS10 inhibits the degradation of α-synuclein, a pathogenic factor associated with Parkinson's disease, by inhibiting chaperone-mediated autophagy. The Journal of biological chemistry, 110292. Advance online publication. [10] Halli-Tierney, A. D., Luker, J., & Carroll, D. G. (2020). Parkinson Disease. American family physician, 102(11), 679–691. [11] Li, Y., Jia, W., Chen, C., Chen, C., Chen, J., Yang, X., & Liu, P. (2025). Identification of biomarkers associated with inflammatory response in Parkinson's disease by bioinformatics and machine learning. PloS one, 20(5), e0320257. [12] Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 124(8), 901–905.
Business Wire
10 hours ago
- Business Wire
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson's Disease Associated With GBA Mutations
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics ('Capsida') today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class intravenously (IV) administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This is the second wholly owned clinical program developed by Capsida with a cleared IND. Both programs utilize a proprietary IV-delivered, blood brain barrier-crossing engineered capsid and proprietary cargo that is detargeted from off-target tissues, like liver and dorsal root ganglia (DRG). In addition, Capsida uses a proprietary manufacturing process and CAP-003 is manufactured in Capsida's state-of-the-art wholly owned Good Manufacturing Practice (GMP) facility. 'PD-GBA is an area of substantial unmet need given the lack of approved treatments that target GCase, which is the protein encoded by the GBA gene, and provide meaningful slowing or halting of disease progression,' said Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics. 'We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year.' About CAP-003 and the Phase 1/2 Clinical Trial In non-human primate (NHP) studies to date, a single IV infusion of CAP-003 resulted in dose-dependent increases in GCase activity in critical brain regions including the substantia nigra, frontal cortex, caudate nucleus, and putamen substantially above the established 30% efficacy threshold expected to restore enzyme activity levels back to normal in patients with PD-GBA. The NHP Good Laboratory Practices (GLP) toxicology study demonstrated a well-tolerated safety profile with no adverse histopathology. Capsida expects to dose the first patient in the Phase 1/2 clinical trial in the third quarter of this year. For more information about the Phase 1/2 clinical trial, please visit (NCT07011771). About Parkinson's disease associated with GBA mutations (PD-GBA) Mutations in GBA, the gene expressing the GCase enzyme, affect up to 15% of Parkinson's patients and are the most common genetic risk factor for PD. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to healthy individuals 1. There are no approved treatments that target GCase and there are no approved disease modifying treatments for PD. Other investigational treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplement GCase enzyme activity in sufficient quantities to overcome the deficit in patients and impact the disease. In an attempt to overcome these challenges, those treatments have required invasive direct brain or cerebrospinal fluid (CSF) administration, with limited results, and a significant burden for patients. About Capsida Biotherapeutics Capsida Biotherapeutics is a clinical-stage, fully integrated next-generation genetic medicines company. It has a central nervous system (CNS) pipeline consisting of disease-modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes its first-in-class investigational treatment for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), CAP-002; and potential best-in-class investigational treatment for Parkinson's disease associated with GBA mutations (PD-GBA) CAP-003. Both have received FDA Investigational New Drug (IND) clearance to initiate clinical trials. Capsida's pipeline also includes a potential best-in-class treatment for Friedreich's ataxia (FA). In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at 1 Leyns, C. E, G. et al (2023). npj Parkinson's Disease, 74(9).
